# Safety and Pharmacokinetics of NRX-1074 in Normal Volunteers

> **NCT01856556** · PHASE1 · COMPLETED · sponsor: **Naurex, Inc, an affiliate of Allergan plc** · enrollment: 100 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** NRX-1074
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01856556
- **Lead sponsor:** Naurex, Inc, an affiliate of Allergan plc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2016-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01856556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01856556, "Safety and Pharmacokinetics of NRX-1074 in Normal Volunteers". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT01856556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*